Vishnu Nayak BadavathVenkatesan JayaprakashSusanta Kumar MondalSandeep AroraOrlando AcevedoAbhishek ThakurRajasekhara Reddy Iska2025-12-182025-12-182020-11-172321-22172321-2225https://doi.org/10.15415/jptrm.2020.82012https://demodspace.chitkara.edu.in/handle/123456789/243Background: Curcumin is a natural phenolic compound obtained from Curcuma longa, with proven human monoamine oxidase (MAO) inhibitory activity, but due to its poor oral bioavailability, blood-brain barrier permeability and extensive metabolism in the liver, it has never been recognized as a drug candidate. Purpose: In this study, the structure-based-drug design (SBDD) was adopted to incorporate the structural features of Curcumin with an aim to improve drug permeability and metabolic stability. Method: A series of ferulic amides (half portion of curcumin) (1-3) and curcumin based pyrazolinescompounds (4-6) were designed and Curcumintested for their membrane permeability and liver microsomal metabolic stability in a various animal in an in-vitro assay system. Conclusion: All the designed compounds showed a significant enhancement in permeability and metabolic stability is achieved through chemical modification.enStructure-based-drug designCurcumin based Pyrazoline analoguesFerulic acid amidesMDCK-II permeability studiesLiver microsomal metabolic stability studiesArticle